CRN Honors Arcserve’s CEO Brannon Lacey as an Innovator on its 2022 Top 100 Executives List
CRN’s annual list recognizes forward-thinking technology leaders who are dedicated to the channel and taking…
Month: August 2022
Infovista to showcase new Ativa™ Automated Assurance & Operations solutions at Digital Transformation World 2022
Enables 360° Assurance and multi-phase automation use cases from a single platform for the first…
Panbela Announces First Patient Enrolled in its Aspire Trial Studying SBP-101 in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
Expects interim data by early 2024 MINNEAPOLIS, Aug. 11, 2022 (GLOBE NEWSWIRE) — Panbela Therapeutics,…
Zealand Pharma Announces Financial Results for the First Half of 2022
Company Announcement No. 34 / 2022 Interim report for H1 2022 Zealand Pharma Announces Financial…
Landos Biopharma Reports Second Quarter 2022 Results and Provides Business Update
Positive Top-Line Results From NX-13 Phase 1b Trial in Ulcerative Colitis Demonstrate a Favorable Safety…
Monopar Therapeutics Reports Second Quarter 2022 Financial Results and Recent Program Developments
Validive® Phase 2b/3 VOICE Trial Continues Adding Sites in the U.S. and Europe and Enrolling…
aTyr Pharma Receives FDA Fast Track Designation for Efzofitimod (ATYR1923) for Treatment of Pulmonary Sarcoidosis
Company is investigating efzofitimod in global pivotal Phase 3 EFZO-FIT™ study in pulmonary sarcoidosis patients…
89bio Reports Second Quarter 2022 Financial Results and Provides Corporate Update
– Reported positive topline results from ENTRIGUE Phase 2 trial of pegozafermin in severe…
Synthetic Biologics Reports Second Quarter 2022 Operational Highlights and Financial Results
-Prioritizing the advancement of novel oncolytic adenovirus (OV) platform- -Cash balance as of August 1,…
Enzo Biochem to Launch Monkeypox Testing Services this Week
NEW YORK, NY, Aug. 11, 2022 (GLOBE NEWSWIRE) — Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo”…
Surrozen Reports Second Quarter 2022 Financial Results
Phase 1 clinical trials of SZN-1326 and SZN-043 initiated and ongoing Preclinical proof-of-concept data for…
Fortress Biotech Subsidiary Helocyte Announces Grant that Could Provide Over $20 Million from National Institute of Allergy and Infectious Diseases for Phase 2 Study of Triplex for Control of Cytomegalovirus in Patients Undergoing Liver Transplantation
MIAMI, Aug. 11, 2022 (GLOBE NEWSWIRE) — Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative…
RAPT Therapeutics Reports Second Quarter 2022 Financial Results
Company maintains strong cash position of $207.3 million SOUTH SAN FRANCISCO, Calif., Aug. 11, 2022…
Motus GI Regains Compliance with Nasdaq Minimum Bid Price Requirement
FORT LAUDERDALE, Fla., Aug. 11, 2022 (GLOBE NEWSWIRE) — Motus GI Holdings, Inc., (NASDAQ: MOTS) (“Motus…
Summit Therapeutics Inc Reports Financial Results and Operational Progress for the Second Quarter Ended June 30, 2022
Menlo Park, California, Aug. 11, 2022 (GLOBE NEWSWIRE) — Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,”…
Vaxxinity Reports Second Quarter 2022 Financial Results and Provides Corporate Updates
• UB-612 Phase 3 COVID-19 Heterologous Boost Trial on Track for Topline Readout in Fourth…
Century Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Updates
– Following the recent submission of the IND application for CNTY-101 and pending FDA clearance,…
Ikena Oncology Reports Second Quarter 2022 Financial Results and Provides a Corporate Update
Advancement across Company’s pipeline towards regulatory and data milestones BOSTON, Aug. 11, 2022 (GLOBE NEWSWIRE)…
Better Choice Company Reports Record Second Quarter 2022 Gross Sales and Provides Corporate Update
Better Choice Reports Record Second Quarter 2022 Gross Sales of $19.8 Million and Net Sales…
Abeona Therapeutics Reports Second Quarter 2022 Financial Results
Disposition of MPS programs allows Abeona to extend runway of current cash into 2Q 2023…